Results 101 to 108 of about 1,870 (108)

A phase Ib dose escalation study of JX-594 (TK-vaccinia virus expressing GM-CSF) administered by biweekly intravenous infusion in patients with metastatic, refractory colorectal carcinoma.

Journal of Clinical Oncology, 2012
e13044 Background: JX-594 is a recombinant vaccinia virus engineered to selectively replicate in and destroy cancer cells while stimulating a systemic anti-tumor immune response and inducing a reduction in tumor blood perfusion. Preclinical data has demonstrated JX-594 activity is enhanced in cells with up regulation of the EGFR pathway.
Young Suk Park, Jeeyun Lee, Ho Yeong Lim, Jihye Lee, Adina Pelusio, James M. Burke, Caroline Breitbach, David H. Kirn   +7 more
openaire   +1 more source

Phase II trial of pexa-vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, in patients with metastatic, refractory renal cell carcinoma (RCC).

Journal of Clinical Oncology, 2018
671 Background: Pexa-Vec is a vaccinia virus engineered to express granulocyte-macrophage colony stimulating factor (GM-CSF), thereby stimulating anti-tumor immunity, direct oncolysis, and tumor vascular disruption. ( Nat Rev Cancer 2009).
Seong-Geun Kim, Hong Koo Ha, Sung-nam Lim, Naomi S. De Silva, Adina Pelusio, Jae Hee Mun, Richard H. Patt, Caroline J. Breitbach, James M. Burke   +8 more
openaire   +1 more source

Abstract LB-283: JX-594, a targeted multi-mechanistic oncolytic poxvirus, selectively infects tumor vasculature and causes acute tumor vascular disruption and necrosis in advanced cancer patients

Cancer Research, 2011
Abstract JX-594 is a first-in-class targeted oncolytic poxvirus designed to selectively replicate in and destroy cancer cells with cell cycle abnormalities and epidermal growth factor receptor (EGFR)/ras pathway activation. Direct oncolysis plus granulocyte macrophage -colony stimulating factor (GM-CSF) expression also stimulates anti ...
Caroline Breitbach, Rozanne Arulanandam, Richard Patt, Naomi De Silva, Kelley Parato, Manijeh Daneshmand, Theresa Hickman, John C. Bell, David H. Kirn   +8 more
openaire   +1 more source

JX-594

Drugs of the Future, 2009
null Kim, S.G., null Hwang, T.H.
openaire   +1 more source

A phase I/II study of JX-594 oncolytic virus in combination with immune checkpoint inhibition in refractory colorectal cancer

European Journal of Cancer, 2020
C. Monge, C. Xie, G. Brar, E. Akoth, S. Webb, D. Mabry, B. Redd, E. Levy, B. Wood, T. Greten   +9 more
openaire   +1 more source

2219 Intratumoral injection of the oncolytic immunotherapeutic Pexa-Vec (JX-594) in liver tumors and hepatocellular carcinoma: Recommendations for clinical practice

European Journal of Cancer, 2015
R. Lencioni, C.W. Kim, S.C. Rose, C.J. Breitbach, J.M. Burke, T. Hickman, D.H. Kirn, N. Stojkowitz, M. Lusky, M. Homerin   +9 more
openaire   +1 more source

124 RANDOMIZED PHASE II CLINICAL TRIAL OF INTRATUMORAL INJECTION OF JX-594, A TARGETED MULTI-MECHANISTIC ONCOLYTIC POXVIRUS, IN PATIENTS WITH HEPATOCELLULAR CARCINOMA

Journal of Hepatology, 2010
J. Heo, T. Reid, H.Y. Lim, L. Ruo, C.W. Kim, M. Bloomston, H.C. Chung, B.G. Rhee, R. Patt, C.J. Breitbach, T. Hickman, J.C. Bell, T.H. Hwang, D.H. Kirn   +13 more
openaire   +1 more source

131 JX-594, A TARGETED MULTI-MECHANISTIC ONCOLYTIC POXVIRUS, IS WELL-TOLERATED AND EXHIBITS ANTI-TUMOR ACTIVITY IN PATIENTS WITH PRIMARY LIVER CANCER AND LIVER METASTASES

Journal of Hepatology, 2011
J. Heo, M. Cho, T. Reid, H.Y. Lim, L. Ruo, C.W. Kim, M. Bloomston, B.-G. Rhee, S.Y. Oh, B.-H. Park, H.C. Chung, R. Patt, C. Breitbach, T.-H. Hwang, J.C. Bell, D.H. Kirn   +15 more
openaire   +1 more source